Nanotechnology in pharmaceutical manufacturing: present innovations and future opportunities

Sanket J Soni

doi:10.37022/jiaps.v9i3.634

Sanket J Soni Associate Director, Department of Project and Portfolio Management, Amneal Pharmaceuticals, New Jersey, USA.

DOI https://doi.org/10.37022/jiaps.v9i3.634

Abstract

Nanotechnology has revolutionized the pharmaceutical industry by enabling the design and delivery of drugs with enhanced precision, efficacy, and safety. This review provides a comprehensive overview of current trends and future prospects in nanotechnology-based drug manufacturing. It explores the application of nanocarriers, such as liposomes, micelles, and nanoparticles, which have improved drug bioavailability, targeted delivery, and reduced side effects. Nano formulations like solid lipid nanoparticles (SLNs) and polymeric nanoparticles are also highlighted for their role in controlled drug release and cancer treatment. Technological innovations, including advanced nanofabrication techniques and 3D printing, are driving the development of complex drug formulations. The review also addresses the challenges in scaling production and the evolving regulatory landscape. Future prospects include the use of nanobots and advanced Nano machines for drug delivery, the integration of nanotechnology in gene therapy and CRISPR, and the exploration of new research and investment opportunities. Ethical and safety considerations, such as the long-term effects of nanomaterials on human health and the environment, are discussed. This review underscores the transformative potential of nanotechnology in drug manufacturing, offering insights into its role in shaping the future of the pharmaceutical industry.

Keywords: Nanotechnology, Drug Manufacturing, Nanocarriers, Nano formulations, Nanofabrication, Personalized Medicine, Nanobots, Gene Therapy, CRISPR, Pharmaceutical Industry

Downloads

Download data is not yet available.

References

1. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-47.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-71.
3. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487-92.
4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.
5. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
6. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-60.
7. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-98.
8. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1-3):149-68.
9. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
10. Namballa M, Adimulapu A, Jesudasan RE. QbD Assisted Optimization of Microwave-assisted Synthesis of Polyacrylamide Grafted Tragacanth: Characterization and Instrumental Analysis. Current Microwave Chemistry. 2024 Apr 1;11(1):16-29.
11. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
12. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.
13. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge and perspectives. AngewChem Int Ed Engl. 2009;48(5):872-97.
14. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631-51.
15. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
16. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-63.
17. Sailor MJ, Park JH. Hybrid nanoparticles for detection and treatment of cancer. Adv Mater. 2012;24(28):3779-802.
18. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6(3):307-18.
19. Manda, P., Popescu, C., Juluri, A. et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. AAPS PharmSciTech 19, 1358–1366 (2018).
20. Lakshmi Narasimha Rao, K., Praneeth Rao, K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. Chromatographia 80, 1211–1224 (2017).
21. Kakulamarri PR, Alikatte KL, Mateti UV (2016) Transdermal Iontophoresis of Non-Polar Drugs: A Mini Review. J Pharm Drug Deliv Res 5:3
22. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. future.;1:6.
23. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
24. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147-66.
25. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Guo R, Chen H. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226-32.
26. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3(1):20-31.
27. Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014;9:1005-23.
28. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biological effects. Nanoscale. 2011;3(3):1167-85.
29. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-9.
30. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, Wurm EM, Yoong C, Robertson TA, Soyer HP, Roberts MS. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470-91.
31. Prasad RY, McGee JK, Killius MG, Suarez DA, Blackman CF, DeMarini DM, Simmons SO. Investigating nanoparticles in drug delivery, pulmonary toxicity, and cancer therapy. Toxicol Sci. 2013;132(2):340-51.
32. Wang F, Yu M, Yan X, Liu X, Zhao Y. Dendrimer-based nanoparticles for cancer diagnosis and therapy. J Control Release. 2017;259:136-48.